Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598806 · ClinicalTrials.gov registry record · Phase 3
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
A Phase 3 study of Bladder Cancer, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 812
- Enrollment target
- 20
- Study locations
NCT00598806 is a Phase 3 study of Bladder Cancer that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 812 participants, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00598806, a Phase 3 study of Bladder Cancer, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 812 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
Conditions Studied
Interventions
- DRUG Placebo
- PROCEDURE TURBT
- DRUG Apaziquone
Study Locations (20)
New York
- Medical & Clinical Research Associates, LLC - Bay Shore
- Urology Associates, PC - Manhasset
- North Shore - LIJ Health System - The Arthur Smith Institute for Urology - New Hyde Park
Georgia
- Urology Enterprises - Marietta
- North Fulton Urology - Roswell
Maryland
- Chesapeake Urology Research Associates - Baltimore
- Chesapeake Urology Research Associates - Towson
New Jersey
- PharmaTrials, Inc. - Male & Female Urology - Hillsborough
- PharmaTrials, Inc. - Hillsborough
North Carolina
- Alliance Urology Specialists - Greensboro
- Piedmont Medical Research - Winston-Salem
California
- Advanced Urology Medical Center Clinical Trials - Anaheim
Florida
- Hal J. Bashein, D.O. - West Palm Beach
Illinois
- Hines VA Hospital - Hines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598806
The ClinicalTrials.gov registry entry for NCT00598806 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 812 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00598806 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT00598806 about?
NCT00598806 is a clinical study titled "Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)". The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
What is the current status of trial NCT00598806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 812 participants. The study started on 2007-08. Estimated completion is 2012-01.
What conditions does trial NCT00598806 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00598806?
The interventions under investigation include: Placebo (DRUG), TURBT (PROCEDURE), Apaziquone (DRUG).
Who is sponsoring clinical trial NCT00598806?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00598806 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.